

**Appl. No.** : **unknown**  
**Filed** : **herewith**

### **AMENDMENTS TO THE CLAIMS**

1-8. (Canceled)

9. (New) A pharmaceutical composition comprising an element selected from the group consisting of: a polynucleotide encoding OC-2, a vector comprising said polynucleotide, OC-2 having the amino acid sequence of SEQ ID NO:2, and a cell line transformed with said vector.

10. (New) A pharmaceutical composition comprising an element selected from the group consisting of: a polynucleotide encoding OC-3, a vector comprising said polynucleotide, OC-3 having the amino acid sequence of SEQ ID NO:3, and a cell line transformed with said vector.

11. (New) The pharmaceutical composition of claim 9, wherein said polynucleotide is a human polynucleotide.

12. (New) The pharmaceutical composition of claim 9, wherein the vector is selected from the group consisting of plasmids, viruses, phagemids, lipid vesicles, in particular cationic vesicles, liposomes and a mixture thereof.

13. (New) A method for the prevention and/or the treatment of type 1 or type 2 diabetes or of disorders linked to diabetes, for the prevention and/or the treatment of cancer and for the prevention and for the treatment of Waardenburg syndrome comprising: administration of the pharmaceutical composition in an amount effective to prevent or reduce symptoms of diabetes, cancer and/or Waardenburg syndrome, wherein said pharmaceutical composition comprises an element selected from the group consisting of: a polynucleotide encoding a peptide of the ONECUT family, a vector comprising said polynucleotide, the polypeptide encoded by said polynucleotide and a cell line transformed with said vector.

14. (New) The method of claim 13, wherein the pharmaceutical composition, which comprises an element selected from the group consisting of: a polynucleotide encoding a peptide of the ONECUT family or a vector comprising said polynucleotide, is administered *ex vivo* by isolating a body fluid or one or more cells from the patient, treating said cells or the cells present in this

**Appl. No.** : **unknown**  
**Filed** : **herewith**

body fluid with said pharmaceutical composition, and reinjecting the transformed cells into said patient.

15. (Previously presented) The method of claim 13 wherein the cancer is melanoma.